Bowen Acquisition Corp
Status: Live Deal
U=S+R
R=S/10
| IPO Proceeds, $M | $69.00M |
|---|---|
| IPO Date | Jul 12, 2023 |
| CEO | Jiangang Luo |
| Left Lead | EarlyBirdCapital |
| IPO Cash in Trust | 101.0% |
| SPAC Tenor | 15 + 3 |
| IPO Sector |
General
Businesses in Asia |
| IPO Geography | Asia |
| Target Company | Qianzhi BioTech |
| Deal Announced | Jan 18, 2024 |
| Deal Size, $M | TBD |
| Deal Sector | Healthcare |
| Deal Geography | Asia |
| SEC Filings | www.sec.gov |
| Approval Vote | TBD |
| Amendment Vote | TBD |
BOWN
BOWNU
BOWNR
| Price | $10.89 |
|---|---|
| Last closing price | $10.89 |
| H/L, today | $10.89 / $10.89 |
| H/L, 52-week | $10.10 / $10.31 |
| Volume, today | 525 |
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on Bowen Acquisition Corp:
- Structure and cap table
- 6 directors & officers
- 13 filings and events
- 2 underwriters
- 5 legal advisors
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Na Gai | 36 | Chairwoman |
| Jiangang Luo | 54 | CEO |
| Jing Lu | 58 | CFO |
| Lawrence Leighton | 88 | Director |
| Wei Li | 44 | Director |
| Jun Zhang | 59 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
| EarlyBirdCapital | BR | 5,100,000 | units |
| Revere Securities | 900,000 | ||
| 6,000,000 | units | ||
| Up-Front UW fee | 2.50 | % | |
| BCMA | 3.50 | % |
Sign in to view more advisor data.